
  
    
      
        Background_NNP
        Type_NNP 1_CD diabetes_NN mellitus_JJ (_( T_NN 1_CD DM_NNP )_) is_VBZ a_DT T_NN cell-mediated_JJ
        autoimmune_JJ disease_NN characterized_VBN by_IN lymphocytic_JJ
        infiltration_NN of_IN the_DT pancreatic_JJ islets_NNS of_IN Langerhans_NNP with_IN
        subsequent_JJ destruction_NN of_IN the_DT insulin-producing_JJ beta_NN cells_NNS
        [_NN 1_CD ]_NN ._. Non-obese_NNP diabetic_JJ (_( NOD_NNP )_) female_JJ mice_NNS ,_, a_DT murine_NN
        model_NN for_IN T_NN 1_CD DM_NNP ,_, spontaneously_RB develop_VB diabetes_NN by_IN 30_CD
        weeks-of-age_JJ ,_, with_IN infiltrating_VBG cells_NNS appearing_VBG around_IN the_DT
        pancreatic_JJ islets_NNS as_RB early_RB as_IN at_IN 3_CD -_: 4_CD weeks-of-age_JJ [_NN 2_CD ]_NN
        ._.
        T_NN 1_CD DM_NNP susceptibility_NN in_IN the_DT NOD_NNP mouse_NN is_VBZ linked_VBN to_TO I-A_NNP
        g_SYM 7_CD ,_, the_DT murine_NN MHC_NNP class_NN II_NNP gene_NN that_IN encodes_NNS a_DT histidine_NN
        at_IN position_NN 56_CD and_CC a_DT serine_NN at_IN position_NN 57_CD in_IN the_DT β_NN chain_NN ,_,
        in_IN place_NN of_IN the_DT more_RBR frequent_JJ proline_NN 56_CD β_NN and_CC aspartic_JJ acid_NN
        57_CD β_NN [_NN 3_CD ]_NN ._. The_DT development_NN of_IN diabetes_NN is_VBZ prevented_VBN in_IN
        NOD_NNP ._. PD_NNP mice_NNS (_( which_WDT are_VBP NOD_NNP mice_NNS with_IN I-A_NNP g_SYM 7_CD )_) that_WDT carry_VBP a_DT β_NN
        chain_NN transgene_NN with_IN site-specific_JJ mutations_NNS that_WDT restore_VB
        proline_NN and_CC aspartic_JJ acid_NN at_IN positions_NNS 56_CD β_NN and_CC 57_CD β_NN ,_,
        respectively_RB [_NN 4_CD ]_NN ._. Furthermore_RB ,_, because_IN of_IN the_DT two_CD amino_JJ
        acid_NN changes_NNS in_IN the_DT additional_JJ (_( transgenic_JJ )_) MHC_NNP class_NN II_NNP
        allele_NN β_NN chain_NN in_IN NOD_NNP ._. PD_NNP mice_NNS ,_, NOD_NNP ._. PD_NNP mice_NNS recognize_VBP three_CD
        additional_JJ peptide_NN epitopes_NNS in_IN the_DT glutamic_JJ acid_NN
        decarboxylase_NN 65_CD (_( GAD_NNP 65_CD )_) autoantigen_NN [_NN 5_CD ]_NN ._.
        Among_IN beta-cell_JJ autoantigens_NNS ,_, GAD_NNP 65_CD is_VBZ an_DT important_JJ
        initial_JJ target_NN of_IN the_DT immune_JJ response_NN that_IN results_NNS in_IN
        beta-cell_JJ destruction_NN and_CC diabetes_NN ,_, in_IN both_DT humans_NNS and_CC NOD_NNP
        mice_NNS [_NN 6_CD 7_CD 8_CD 9_CD ]_NN ._. While_IN both_DT humoral_NN and_CC cellular_JJ
        responses_NNS to_TO GAD_NNP 65_CD occur_VB as_RB early_RB as_IN 4_CD weeks_NNS of_IN age_NN in_IN NOD_NNP
        mice_NNS [_NN 8_CD ]_NN ,_, there_EX is_VBZ considerable_JJ evidence_NN that_IN
        beta-cell-specific_JJ T_NN 
        H_NNP 1_CD cells_NNS are_VBP the_DT effectors_NNS of_IN T_NN 1_CD DM_NNP ,_,
        whereas_IN T_NN 
        H_NNP 2_CD cells_NNS appear_VBP to_TO have_VB a_DT protective_JJ
        role_NN [_NN 10_CD ]_NN ._. Accordingly_RB ,_, a_DT shift_NN of_IN the_DT autoimmune_JJ
        response_NN from_IN T_NN 
        H_NNP 1_CD to_TO T_NN 
        H_NNP 2_CD predominance_NN has_VBZ represented_VBN a_DT
        promising_JJ strategy_NN for_IN prevention_NN of_IN diabetes_NN and_CC other_JJ T_NN 
        H_NNP 1_CD -_: mediated_JJ autoimmune_JJ diseases_NNS ._.
        For_IN example_NN ,_, administration_NN of_IN GAD_NNP 65_CD to_TO young_JJ NOD_NNP mice_NNS
        has_VBZ been_VBN shown_VBN to_TO prevent_VB insulitis_NNS and_CC diabetes_NN [_NN 8_CD 9_CD ]_NN ,_,
        apparently_RB via_IN induction_NN of_IN CD_NNP 4_CD +_NN regulatory_JJ T_NN cells_NNS with_IN a_DT
        T_NN 
        H_NNP 2_CD phenotype_NN [_NN 10_CD ]_NN ._. Similarly_RB ,_,
        treatment_NN with_IN immunodominant_NN peptides_NNS of_IN myelin_NN can_MD
        prevent_VB or_CC reverse_VB experimental_JJ autoimmune_JJ
        encephalomyelitis_NNS (_( EAE_NNP )_) ,_, a_DT T_NN 
        H_NNP 1_CD -_: associated_VBN inducible_JJ "_'' autoimmune_JJ "_''
        disorder_NN that_WDT is_VBZ widely_RB used_VBN as_IN a_DT model_NN for_IN human_JJ multiple_JJ
        sclerosis_NN [_NN 11_CD 12_CD 13_CD ]_NN ._.
        Unfortunately_RB ,_, recent_JJ work_NN indicates_VBZ that_IN the_DT
        application_NN of_IN strategies_NNS to_TO shift_VB autoimmune_JJ responses_NNS
        from_IN T_NN 
        H_NNP 1_CD to_TO T_NN 
        H_NNP 2_CD predominance_NN is_VBZ not_RB without_IN risk_NN ._.
        Thus_RB ,_, some_DT of_IN us_PRP recently_RB showed_VBD that_DT administration_NN of_IN two_CD
        self_NN peptides_NNS that_WDT can_MD induce_VB EAE_NNP ,_, myelin_NN proteolipid_NN
        protein_NN peptide_NN 139_CD to_TO 151_CD (_( PLP_NNP 139_CD -_: 151_CD )_) or_CC myelin_NN
        oligodendrocyte_NN glycoprotein_NN peptide_NN 35_CD -_: 55_CD (_( MOG_NNP 35_CD -_: 55_CD )_) ,_, can_MD
        result_VB in_IN severe_JJ anaphylactic_JJ reactions_NNS [_NN 14_CD ]_NN ._. This_DT
        result_NN clearly_RB indicated_VBD that_IN severe_JJ allergic_JJ reactions_NNS to_TO
        self_NN peptides_NNS can_MD occur_VB in_IN mice_NNS that_WDT have_VBP been_VBN 
        induced_VBN to_TO express_VB pathology_NN (_( i_NNP ._. e_SYM ._. ,_,
        EAE_NNP )_) related_VBN to_TO "_'' autoimmunity_NN "_'' to_TO these_DT peptides_NNS ._. However_RB ,_,
        it_PRP was_VBD initially_RB unclear_JJ whether_IN anaphylactic_JJ reactivity_NN
        also_RB could_MD be_VB elicited_JJ to_TO self_NN peptides_NNS that_WDT have_VBP been_VBN
        implicated_VBN in_IN the_DT development_NN of_IN a_DT 
        spontaneous_JJ autoimmune_JJ disorder_NN ._.
        In_IN the_DT present_JJ study_NN ,_, we_PRP show_VBP that_IN anti-peptide_JJ
        autoantibodies_NNS and_CC fatal_JJ anaphylactic_JJ reactions_NNS can_MD be_VB
        elicited_JJ by_IN immunodominant_NN GAD_NNP 65_CD peptides_NNS in_IN NOD_NNP mice_NNS that_WDT
        have_VBP been_VBN injected_VBN with_IN these_DT peptides_NNS intraperitoneally_RB in_IN
        incomplete_JJ Freund_NNP 's_POS adjuvant_NN (_( IFA_NNP )_) ,_, as_IN part_NN of_IN an_DT attempt_NN
        to_TO induce_VB "_'' tolerance_NN "_'' and_CC prevent_VB the_DT spontaneous_JJ
        development_NN of_IN T_NN 1_CD DM_NNP ._. Moreover_RB ,_, while_IN this_DT manuscript_NN was_VBD in_IN
        review_NN ,_, Liu_NNP and_CC colleagues_NNS reported_VBD that_IN anti-peptide_JJ
        autoantibodies_NNS and_CC fatal_JJ anaphylaxis_NNS can_MD be_VB induced_VBN in_IN NOD_NNP
        mice_NNS that_WDT have_VBP been_VBN immunized_JJ with_IN insulin_NN B_NNP chain_NN peptides_NNS
        B_NNP :_: 9_CD -_: 23_CD or_CC B_NNP :_: 13_CD -_: 23_CD [_NN 15_CD ]_NN ._. However_RB ,_, in_IN the_DT Liu_NNP 
        et_CC al_NN ._. study_NN ,_, the_DT peptides_NNS were_VBD
        administered_VBN subcutaneously_RB in_IN saline_NN without_IN adjuvant_NN ._. As_IN
        reviewed_VBN in_IN Liu_NNP 
        et_CC al_NN ._. ,_, [_NN 15_CD ]_NN several_JJ lines_NNS of_IN
        evidence_NN indicate_VBP that_IN amino_JJ acids_NNS 9_CD -_: 23_CD of_IN the_DT insulin_NN B_NNP
        chain_NN also_RB represent_VB a_DT major_JJ target_NN of_IN anti-islet_JJ
        autoimmunity_NN in_IN T_NN 1_CD DM_NNP ._. Taken_VBN together_RB with_IN the_DT findings_NNS
        reported_VBD herein_NN ,_, this_DT work_NN indicates_VBZ that_IN anaphylactic_JJ
        reactions_NNS can_MD be_VB elicited_JJ in_IN mice_NNS that_WDT have_VBP been_VBN immunized_JJ
        with_IN pancreatic_JJ islet-associated_JJ self-peptides_JJ that_IN also_RB
        represent_VB significant_JJ targets_NNS of_IN autoimmunity_NN in_IN T_NN 1_CD DM_NNP ._.
      
      
        Results_NNS
        
          Anaphylactic_NNP responses_NNS to_TO GAD_NNP 65_CD and_CC PD_NNP
          peptides_NNS
          In_IN an_DT attempt_NN to_TO induce_VB a_DT T_NN 
          H_NNP 2_CD shift_NN ,_, [_NN 19_CD 20_CD ]_NN 8_CD to_TO 9_CD week_NN old_JJ
          female_JJ NOD_NNP mice_NNS (_( I-A_NNP g_SYM 7_CD )_) were_VBD immunized_JJ by_IN 3_CD weekly_JJ i_NNP ._. p_NN ._.
          injections_NNS of_IN the_DT immunodominant_NN G_NNP 7_CD peptides_NNS (_( GAD_NNP
          206_CD -_: 226_CD /_NN 217_CD -_: 236_CD /_NN 286_CD -_: 300_CD )_) or_CC of_IN the_DT additional_JJ GAD_NNP 65_CD
          peptides_NNS identified_VBN in_IN NOD_NNP ._. PD_NNP mice_NNS (_( I-A_NNP NOD_NNP /_NN PD_NNP )_) (_( GAD_NNP
          333_CD -_: 345_CD /_NN K_NNP 458_CD -_: 470_CD R_NN )_) in_IN IFA_NNP [_NN 5_CD ]_NN ._. As_IN noted_VBD in_IN the_DT
          background_NN section_NN ,_, PD_NNP peptides_NNS are_VBP not_RB immunodominant_NN in_IN
          NOD_NNP mice_NNS ._. Indeed_RB ,_, we_PRP originally_RB included_VBD the_DT PD-immunized_NNP
          group_NN because_IN PD_NNP peptides_NNS are_VBP the_DT immunodominant_NN epitopes_NNS
          that_WDT are_VBP presented_VBN in_IN transgenic_JJ NOD_NNP ._. PD_NNP mice_NNS that_WDT do_VBP 
          not_RB get_VB diabetes_NN [_NN 4_CD 5_CD ]_NN ._.
          Because_IN of_IN their_PRP$ unknown_JJ ,_, and_CC potentially_RB even_RB
          protective_JJ ,_, role_NN in_IN the_DT diabetes-resistant_JJ NOD_NNP ._. PD_NNP strain_NN ,_,
          we_PRP felt_VBD that_IN it_PRP was_VBD important_JJ to_TO assess_VB whether_IN ,_, through_IN
          a_DT peptide_NN therapy_NN regimen_NN ,_, PD_NNP peptides_NNS might_MD be_VB able_JJ to_TO
          protect_VB against_IN diabetes_NN by_IN shifting_VBG T_NN 
          H_NNP 1_CD to_TO T_NN 
          H_NNP 2_CD responses_NNS in_IN NOD_NNP mice_NNS ._. As_IN our_PRP$
          study_NN unfolded_VBD ,_, and_CC we_PRP found_VBD that_IN G_NNP 7_CD peptide_NN therapy_NN
          induced_VBD anaphylactic_JJ reactivity_NN in_IN NOD_NNP mice_NNS ,_, we_PRP felt_VBD that_IN
          it_PRP was_VBD important_JJ to_TO evaluate_VB whether_IN PD_NNP peptides_NNS might_MD
          also_RB induce_VB allergic_JJ responses_NNS in_IN the_DT NOD_NNP strain_NN ._.
          As_IN demonstrated_VBN in_IN our_PRP$ study_NN ,_, immunization_NN of_IN NOD_NNP mice_NNS
          with_IN PD_NNP peptides_NNS can_MD induce_VB both_DT a_DT specific_JJ IgG_NNP 1_CD response_NN
          and_CC also_RB anaphylactic_JJ reactivity_NN ._. On_IN the_DT other_JJ hand_NN ,_, as_IN
          might_MD be_VB predicted_VBN ,_, PD_NNP peptides_NNS induced_VBD a_DT less_RBR robust_JJ
          IgG_NNP 1_CD response_NN (_( Figure_NN 2_LS )_) and_CC also_RB a_DT lower_JJR incidence_NN and_CC
          severity_NN of_IN anaphylaxis_NNS (_( see_VB Table_NNP 1_CD and_CC Figure_NN 1_LS )_) when_WRB
          injected_VBN into_IN NOD_NNP mice_NNS than_IN did_VBD G_NNP 7_CD peptides_NNS ._. In_IN an_DT
          attempt_NN to_TO induce_VB anaphylactic_JJ reactivity_NN to_TO peptides_NNS
          known_VBN to_TO induce_VB T_NN 
          H_NNP 2_CD responses_NNS associated_VBN with_IN allergic_JJ
          reactions_NNS ,_, NOD_NNP mice_NNS were_VBD immunized_JJ using_VBG the_DT same_JJ
          protocol_NN with_IN hen_NN egg_NN lysozyme_NN and_CC ovalbumin_NN peptides_NNS
          (_( HEL_NNP 81_CD -_: 96_CD ,_, OVA_NNP 323_CD -_: 339_CD )_) [_NN 21_CD 22_CD 23_CD ]_NN ._. As_IN a_DT negative_JJ
          control_NN ,_, NOD_NNP mice_NNS received_VBD 3_CD weekly_JJ injections_NNS of_IN saline_NN
          emulsified_JJ in_IN IFA_NNP ._. Four_CD weeks_NNS after_IN the_DT last_NN of_IN the_DT 3_CD
          i_NNP ._. p_NN ._. injections_NNS of_IN peptides_NNS /_NN IFA_NNP or_CC saline_NN /_NN IFA_NNP ,_, mice_NNS
          injected_VBN with_IN peptides_NNS /_NN IFA_NNP were_VBD challenged_VBN i_NNP ._. p_NN ._. with_IN the_DT
          same_JJ peptides_NNS used_VBN for_IN the_DT immunizations_NNS dissolved_VBN in_IN
          saline_NN ,_, whereas_IN mice_NNS that_WDT had_VBD been_VBN injected_VBN with_IN
          saline_NN /_NN IFA_NNP were_VBD challenged_VBN with_IN saline_NN alone_RB ._. By_IN the_DT day_NN
          of_IN challenge_NN ,_, 10_CD -_: 15_CD %_NN of_IN all_DT mice_NNS had_VBD developed_VBN diabetes_NN ,_,
          with_IN the_DT exception_NN of_IN the_DT mice_NNS in_IN the_DT saline_NN group_NN
          (_( 0_CD %_NN )_) ._.
          All_DT of_IN the_DT mice_NNS challenged_VBN with_IN G_NNP 7_CD peptides_NNS developed_VBD
          severe_JJ anaphylactic_JJ shock_NN (_( 100_CD %_NN ;_: 14_CD /_NN 14_CD )_) ,_, with_IN the_DT
          majority_NN of_IN them_PRP dying_VBG within_IN 30_CD minutes_NNS after_IN the_DT
          injection_NN (_( 86_CD %_NN ;_: 12_CD /_NN 14_CD )_) (_( Table_NNP 1_LS )_) ._. In_IN addition_NN to_TO the_DT
          classical_JJ signs_NNS of_IN anaphylaxis_NNS ,_, such_JJ as_IN reddening_VBG of_IN the_DT
          skin_NN ,_, prostration_NN and_CC respiratory_JJ impairment_NN ,_, the_DT mice_NNS
          underwent_VBD a_DT dramatic_JJ drop_NN in_IN body_NN temperature_NN (_( Fig_NNP ._. 1_LS )_) ,_,
          which_WDT confirmed_VBD the_DT presence_NN of_IN anaphylactic_JJ shock_NN ._.
          Moreover_RB ,_, the_DT death_NN rate_NN from_IN anaphylaxis_NNS was_VBD
          substantially_RB higher_JJR than_IN in_IN any_DT other_JJ group_NN in_IN which_WDT
          anaphylaxis_NNS occurred_VBD (_( Table_NNP 1_LS )_) ._.
          On_IN the_DT other_JJ hand_NN ,_, the_DT clinical_JJ and_CC physiological_JJ
          features_NNS of_IN anaphylaxis_NNS elicited_JJ by_IN the_DT G_NNP 7_CD peptides_NNS were_VBD
          similar_JJ to_TO those_DT observed_VBD in_IN age-_NN and_CC gender-matched_JJ NOD_NNP
          mice_NNS undergoing_VBG IgE-mediated_NNP passive_JJ systemic_JJ anaphylaxis_NNS
          (_( Fig_NNP ._. 1_LS )_) ._. Although_IN the_DT death_NN rate_NN was_VBD significantly_RB
          higher_JJR in_IN the_DT G_NNP 7_CD challenged_VBN NOD_NNP group_NN (_( 86_CD %_NN ;_: 12_CD /_NN 14_CD )_)
          compared_VBN to_TO the_DT IgE-sensitized_NNP ,_, DNP-HSA_NNP challenged_VBD group_NN
          (_( none_NN )_) (_( P_NN =_SYM <_NN 0_CD ._. 0001_CD by_IN Fisher_NNP 's_POS exact_JJ test_NN ,_, Table_NNP 1_LS )_) ,_,
          those_DT mice_NNS in_IN either_DT group_NN that_WDT developed_VBD anaphylaxis_NNS
          exhibited_VBN quite_RB similar_JJ drops_NNS in_IN body_NN temperature_NN (_( Fig_NNP ._.
          1_LS B_NNP )_) ._. Similarly_RB ,_, while_IN the_DT group_NN of_IN mice_NNS that_WDT was_VBD
          challenged_VBN with_IN G_NNP 7_CD peptides_NNS exhibited_VBN a_DT higher_JJR incidence_NN
          of_IN anaphylactic_JJ responses_NNS than_IN did_VBD the_DT group_NN challenged_VBN
          with_IN HEL_NNP /_NN OVA_NNP peptides_NNS (_( Table_NNP 1_LS )_) ,_, the_DT temperature_NN changes_NNS
          (_( Fig_NNP ._. 1_LS B_NNP )_) and_CC death_NN rates_NNS (_( Table_NNP 1_LS )_) in_IN mice_NNS that_WDT did_VBD
          develop_VB a_DT reaction_NN were_VBD quite_RB similar_JJ ._.
          None_NN of_IN the_DT naïve_NN age_NN /_NN gender-matched_JJ NOD_NNP mice_NNS (_( these_DT
          mice_NNS received_VBD no_DT injection_NN prior_RB to_TO challenge_VB )_) that_WDT were_VBD
          challenged_VBN with_IN G_NNP 7_CD peptides_NNS showed_VBD any_DT signs_NNS of_IN
          anaphylaxis_NNS (_( 0_CD /_NN 9_CD ;_: P_NN <_NN 0_CD ._. 0001_CD by_IN Fisher_NNP 's_POS exact_JJ test_NN
          for_IN comparison_NN vs_NNS ._. G_NNP 7_CD immunized_JJ ,_, G_NNP 7_CD challenged_VBN mice_NNS )_)
          (_( Table_NNP 1_CD ,_, Fig_NNP ._. 1_LS )_) ._. This_DT result_NN indicates_VBZ that_IN priming_VBG of_IN
          these_DT mice_NNS with_IN G_NNP 7_CD peptides_NNS is_VBZ required_VBN for_IN the_DT
          elicitation_NN of_IN the_DT allergic_JJ response_NN ._.
          Of_IN the_DT mice_NNS immunized_JJ with_IN the_DT PD_NNP peptides_NNS ,_, that_WDT are_VBP
          not_RB immunodominant_NN in_IN NOD_NNP mice_NNS ,_, 43_CD %_NN (_( 3_CD /_NN 7_CD )_) developed_VBN
          anaphylactic_JJ shock_NN at_IN the_DT time_NN of_IN challenge_NN with_IN PD_NNP
          peptides_NNS (_( Table_NNP 1_LS )_) ._. Thus_RB ,_, the_DT incidence_NN of_IN anaphylactic_JJ
          shock_NN in_IN mice_NNS immunized_JJ and_CC challenged_VBN with_IN PD_NNP peptides_NNS
          was_VBD significantly_RB lower_JJR than_IN that_DT in_IN mice_NNS immunized_JJ and_CC
          challenged_VBN with_IN immunodominant_NN G_NNP 7_CD peptides_NNS (_( P_NN =_SYM 0_CD ._. 0058_CD by_IN
          Fisher_NNP 's_POS exact_JJ test_NN )_) ._. Moreover_RB ,_, of_IN those_DT PD-immunized_NNP ,_,
          PD-challenged_NNP mice_NNS that_WDT did_VBD exhibit_NN an_DT anaphylactic_JJ
          reaction_NN ,_, the_DT drop_NN in_IN temperature_NN was_VBD less_RBR sustained_JJ than_IN
          that_DT in_IN those_DT mice_NNS in_IN the_DT other_JJ groups_NNS that_WDT exhibited_VBN
          anaphylaxis_NNS (_( Fig_NNP ._. 1_LS B_NNP )_) and_CC only_RB 1_CD of_IN these_DT mice_NNS died_VBD (_( 33_CD %_NN )_)
          (_( Table_NNP 1_LS )_) ._. In_IN accord_NN with_IN these_DT results_NNS ,_, immunization_NN of_IN
          the_DT NOD_NNP mice_NNS with_IN PD_NNP peptides_NNS produced_VBD a_DT less_RBR robust_JJ
          specific_JJ IgG_NNP 1_CD antibody_NN response_NN than_IN did_VBD immunization_NN
          with_IN the_DT immunodominant_NN G_NNP 7_CD peptides_NNS (_( see_VB below_IN )_) ._. As_IN
          expected_VBN ,_, none_NN of_IN the_DT mice_NNS immunized_JJ with_IN saline_NN /_NN IFA_NNP
          alone_RB developed_VBD anaphylaxis_NNS upon_IN i_NNP ._. p_NN ._. challenge_NN with_IN
          saline_NN (_( Table_NNP 1_CD ,_, Fig_NNP ._. 1_LS )_) ._.
          Notably_RB ,_, in_IN the_DT mice_NNS immunized_JJ with_IN G_NNP 7_CD ,_, PD_NNP or_CC HEL_NNP /_NN OVA_NNP
          emulsified_JJ in_IN IFA_NNP ,_, anaphylactic_JJ responses_NNS were_VBD also_RB
          provoked_VBN by_IN the_DT third_JJ i_NNP ._. p_NN ._. immunization_NN with_IN peptides_NNS
          (_( 10_CD /_NN 12_CD in_IN the_DT G_NNP 7_CD group_NN ;_: 3_CD /_NN 4_CD for_IN PD_NNP ,_, 3_CD /_NN 10_CD for_IN HEL_NNP /_NN OVA_NNP )_) ._.
          However_RB ,_, these_DT anaphylactic_JJ responses_NNS were_VBD less_RBR severe_JJ
          than_IN those_DT induced_VBN by_IN subsequent_JJ peptide_NN challenge_NN of_IN the_DT
          same_JJ mice_NNS ,_, with_IN a_DT less_RBR dramatic_JJ drop_NN in_IN body_NN temperature_NN
          (_( data_NNS not_RB shown_VBN )_) and_CC no_DT deaths_NNS ._. Finally_RB ,_, although_IN the_DT
          numbers_NNS of_IN mice_NNS that_WDT had_VBD developed_VBN diabetes_NN by_IN the_DT day_NN of_IN
          peptide_NN challenge_NN in_IN each_DT of_IN the_DT immunized_JJ groups_NNS was_VBD
          small_JJ (_( 10_CD -_: 15_CD %_NN )_) ,_, there_EX were_VBD no_DT statistically_RB significant_JJ
          differences_NNS in_IN the_DT incidence_NN of_IN anaphylactic_JJ reactions_NNS in_IN
          these_DT mice_NNS vs_NNS ._. mice_NNS that_WDT were_VBD normoglycemic_JJ at_IN the_DT time_NN
          of_IN peptide_NN challenge_NN ._.
        
        
          IgG_NNP 1_CD ,_, IgG_NNP 2_CD a_DT and_NN IgE_NNP responses_NNS
          Antibody_NNP responses_NNS were_VBD analyzed_VBN by_IN ELISA_NNP in_IN serum_NN
          obtained_VBD 2_CD to_TO 3_CD days_NNS before_IN the_DT 4_CD week_NN challenge_NN with_IN
          peptides_NNS or_CC saline_NN ._. Mice_NNS immunized_JJ with_IN the_DT G_NNP 7_CD peptides_NNS
          had_VBD high_JJ IgG_NNP titers_NNS against_IN the_DT G_NNP 7_CD peptides_NNS ,_, with_IN levels_NNS
          of_IN IgG_NNP 1_CD being_VBG significantly_RB higher_JJR than_IN those_DT of_IN IgG_NNP 2_CD a_DT (_( P_NN
          <_NN 0_CD ._. 0001_CD by_IN Mann-_NNP Whitney_NNP U_NNP test_NN ,_, 2_CD -_: tailed_JJ ;_: Figure_NN 2_CD A_DT )_) ._.
          Anti-_NNP G_NNP 7_CD IgG_NNP antibodies_NNS generally_RB were_VBD not_RB detectable_JJ in_IN
          the_DT other_JJ groups_NNS (_( PD-_NNP or_CC HEL_NNP /_NN OVA-_NNP immunized_JJ ,_, or_CC IFA_NNP
          alone_RB )_) or_CC in_IN the_DT non-injected_JJ (_( naïve_NN )_) mice_NNS ._. The_DT two_CD
          exceptions_NNS were_VBD a_DT single_JJ non-immunized_JJ mouse_NN with_IN anti-_NN G_NNP 7_CD
          IgG_NNP 1_CD antibodies_NNS (_( at_IN a_DT serum_NN concentration_NN of_IN 90_CD μg_NN /_NN ml_NN )_) ,_,
          and_CC one_CD mouse_NN immunized_JJ with_IN HEL_NNP /_NN OVA_NNP with_IN anti-_NN G_NNP 7_CD IgG_NNP 2_CD a_DT
          antibodies_NNS (_( at_IN a_DT serum_NN concentration_NN of_IN 492_CD ng_NN /_NN ml_NN )_) ._.
          Anti-peptide_NNP IgG_NNP 1_CD and_CC IgG_NNP 2_CD a_DT antibodies_NNS also_RB were_VBD detected_VBN
          in_IN PD-_NNP (_( Figure_NN 2_CD B_NNP )_) and_CC HEL_NNP /_NN OVA-_NNP (_( Figure_NN 2_CD C_NNP )_) immunized_JJ
          mice_NNS ,_, although_IN the_DT magnitude_NN of_IN the_DT antibody_NN responses_NNS to_TO
          these_DT peptides_NNS (_( especially_RB the_DT IgG_NNP 1_CD response_NN )_) were_VBD
          substantially_RB less_JJR than_IN those_DT to_TO the_DT G_NNP 7_CD peptides_NNS ._.
          Total_NNP IgE_NNP concentrations_NNS were_VBD slightly_RB ,_, but_CC
          significantly_RB ,_, higher_JJR in_IN the_DT peptide-immunized_JJ groups_NNS
          (_( G_NNP 7_CD ,_, PD_NNP ,_, or_CC HEL_NNP /_NN OVA_NNP )_) compared_VBN to_TO those_DT in_IN mice_NNS injected_VBN
          with_IN IFA_NNP and_CC saline_NN alone_RB (_( Figure_NN 3_LS )_) ._. However_RB ,_, the_DT serum_NN
          concentrations_NNS of_IN total_JJ IgE_NNP were_VBD very_RB similar_JJ in_IN the_DT mice_NNS
          that_WDT had_VBD been_VBN immunized_JJ with_IN G_NNP 7_CD ,_, PD_NNP or_CC HEL_NNP /_NN OVA_NNP peptides_NNS
          (_( Figure_NN 3_LS )_) ._.
        
      
      
        Discussion_NNP
        This_DT study_NN clearly_RB demonstrates_VBZ that_IN i_NNP ._. p_NN ._. immunization_NN
        of_IN NOD_NNP mice_NNS with_IN preparations_NNS of_IN GAD_NNP 65_CD self_NN peptides_NNS in_IN IFA_NNP
        can_MD cause_VB a_DT marked_VBN shift_NN towards_IN a_DT T_NN 
        H_NNP 2_CD like_IN response_NN ,_, as_IN reflected_VBN by_IN high_JJ
        levels_NNS of_IN IgG_NNP 1_CD ._. Similarly_RB ,_, Liu_NNP 
        et_CC al_NN ._. recently_RB demonstrated_VBN that_IN
        strong_JJ IgG_NNP 1_CD responses_NNS can_MD be_VB induced_VBN in_IN NOD_NNP mice_NNS that_WDT have_VBP
        been_VBN immunized_JJ subcutaneously_RB with_IN insulin_NN B_NNP chain_NN peptides_NNS
        administered_VBN in_IN physiological_JJ saline_NN [_NN 15_CD ]_NN ._. However_RB ,_, both_DT
        studies_NNS showed_VBD that_IN anaphylaxis_NNS can_MD be_VB induced_VBN in_IN such_JJ mice_NNS
        upon_IN subsequent_JJ re-challenge_JJ with_IN preparations_NNS of_IN the_DT
        peptides_NNS used_VBN for_IN immunization_NN [_NN 15_CD ]_NN ._. Moreover_RB ,_, the_DT
        anaphylactic_JJ reactions_NNS in_IN mice_NNS that_WDT had_VBD been_VBN immunized_JJ and_CC
        challenged_VBN with_IN G_NNP 7_CD peptides_NNS were_VBD severe_JJ ,_, with_IN reductions_NNS in_IN
        body_NN temperature_NN that_WDT were_VBD very_RB similar_JJ to_TO those_DT observed_VBD
        in_IN mice_NNS exhibiting_VBG IgE-dependent_NNP passive_JJ systemic_JJ
        anaphylaxis_NNS and_CC with_IN a_DT very_RB high_JJ fatality_NN rate_NN (_( 12_CD /_NN 14_CD mice_NNS ,_,
        or_CC 86_CD %_NN )_) ._. Anaphylaxis_NNP also_RB developed_VBD in_IN some_DT NOD_NNP mice_NNS that_WDT
        had_VBD been_VBN immunized_JJ and_CC challenged_VBN with_IN preparations_NNS of_IN PD_NNP
        peptides_NNS (_( that_WDT are_VBP not_RB immunodominant_NN in_IN NOD_NNP mice_NNS )_) ,_,
        although_IN both_DT the_DT drop_NN in_IN body_NN temperature_NN and_CC the_DT death_NN
        rate_NN in_IN these_DT mice_NNS were_VBD significantly_RB less_JJR than_IN those_DT
        observed_VBN in_IN the_DT mice_NNS immunized_JJ and_CC challenged_VBN with_IN G_NNP 7_CD
        peptides_NNS ._.
        There_EX were_VBD both_DT similarities_NNS and_CC differences_NNS between_IN our_PRP$
        findings_NNS in_IN the_DT NOD_NNP mouse_NN model_NN of_IN T_NN 1_CD DM_NNP and_CC those_DT in_IN the_DT
        EAE_NNP model_NN [_NN 14_CD ]_NN ._. Expression_NNP of_IN EAE_NNP requires_VBZ specific_JJ
        immunization_NN with_IN self_NN peptides_NNS (_( e_SYM ._. g_SYM ._. ,_, PLP_NNP 139_CD -_: 151_CD or_CC
        MOG_NNP 35_CD -_: 55_CD )_) ,_, and_CC these_DT peptides_NNS generally_RB are_VBP administered_VBN in_IN
        complete_JJ Freund_NNP 's_POS adjuvant_NN (_( CFA_NNP )_) ._. By_IN contrast_NN ,_, T_NN 1_CD DM_NNP
        develops_VBZ spontaneously_RB in_IN NOD_NNP mice_NNS ._. On_IN the_DT other_JJ hand_NN ,_,
        induction_NN of_IN anaphylactic_JJ reactivity_NN in_IN NOD_NNP mice_NNS appeared_VBD
        to_TO require_VB immunization_NN of_IN the_DT mice_NNS with_IN GAD_NNP 65_CD peptides_NNS (_( in_IN
        this_DT model_NN ,_, in_IN IFA_NNP )_) ,_, as_IN naïve_NN NOD_NNP mice_NNS challenged_VBN with_IN G_NNP 7_CD
        peptides_NNS exhibited_VBN no_DT detectible_JJ reactions_NNS ,_, and_CC none_NN of_IN
        them_PRP died_VBD (_( Table_NNP 1_LS )_) ._. Thus_RB ,_, in_IN both_DT the_DT EAE_NNP model_NN [_NN 14_CD ]_NN and_CC
        the_DT NOD_NNP T_NN 1_CD DM_NNP model_NN (_( this_DT study_NN ,_, and_CC that_IN of_IN Liu_NNP 
        et_CC al_NN ._. ,_, [_NN 15_CD ]_NN )_) some_DT form_NN of_IN
        artificial_JJ "_'' immunization_NN "_'' with_IN a_DT self_NN peptide_NN preparation_NN
        appears_VBZ to_TO be_VB required_VBN for_IN the_DT development_NN of_IN anaphylactic_JJ
        reactivity_NN to_TO "_'' self_NN "_'' ._. This_DT of_IN course_NN is_VBZ not_RB a_DT surprising_JJ
        result_NN ._. Indeed_RB ,_, it_PRP is_VBZ challenging_VBG to_TO conceive_VB of_IN any_DT
        possible_JJ selective_JJ advantage_NN that_WDT would_MD be_VB conferred_VBD by_IN a_DT
        propensity_NN to_TO develop_VB ,_, under_IN "_'' natural_JJ "_'' conditions_NNS ,_,
        potentially_RB fatal_JJ allergic_JJ reactions_NNS to_TO components_NNS of_IN self_NN ._.
        It_PRP remains_VBZ to_TO be_VB determined_VBN whether_IN self_NN peptide_NN
        immunization_NN protocols_NNS that_WDT induce_VB anaphylactic_JJ reactivity_NN
        do_VBP so_RB simply_RB because_IN of_IN the_DT manner_NN in_IN which_WDT they_PRP present_VBP
        large_JJ amounts_NNS of_IN self_NN peptides_NNS to_TO the_DT immune_JJ system_NN ,_, or_CC
        because_IN of_IN other_JJ factors_NNS ,_, such_JJ as_IN the_DT presence_NN in_IN the_DT
        peptide_NN preparations_NNS of_IN aggregates_NNS or_CC other_JJ components_NNS
        beside_IN self_NN peptide_NN monomers_NNS ._.
        Whatever_WDT the_DT underlying_VBG reason_NN (_( s_VBZ )_) for_IN the_DT development_NN of_IN
        anaphylactic_JJ reactivity_NN to_TO these_DT self_NN peptide_NN preparations_NNS ,_,
        in_IN both_DT the_DT EAE_NNP and_CC the_DT NOD_NNP T_NN 1_CD DM_NNP models_NNS ,_, anaphylactic_JJ
        reactions_NNS occurred_VBD in_IN mice_NNS that_WDT had_VBD developed_VBN strong_JJ IgG_NNP 1_CD
        responses_NNS to_TO the_DT relevant_JJ self_NN peptides_NNS ,_, with_IN only_RB modest_JJ
        changes_NNS in_IN total_JJ IgE_NNP levels_NNS ._. In_IN humans_NNS ,_, antigen-specific_JJ
        anaphylactic_JJ reactivity_NN is_VBZ thought_VBN to_TO be_VB mediated_JJ solely_RB
        (_( or_CC primarily_RB )_) by_IN IgE_NNP antibodies_NNS ,_, whereas_IN it_PRP has_VBZ long_RB been_VBN
        known_VBN that_IN either_DT IgE_NNP or_CC IgG_NNP 1_CD antibodies_NNS can_MD mediate_VB
        anaphylaxis_NNS in_IN mice_NNS (_( reviewed_VBN in_IN [_NN 14_CD 15_CD ]_NN and_CC [_NN 17_CD ]_NN )_) ._.
        However_RB ,_, it_PRP has_VBZ been_VBN reported_VBN that_IN IgG_NNP 1_CD -_: dependent_JJ
        anaphylaxis_NNS in_IN the_DT mouse_NN is_VBZ associated_VBN with_IN substantially_RB
        less_RBR histological_JJ evidence_NN of_IN mast_NN cell_NN degranulation_NN than_IN
        is_VBZ observed_VBN in_IN IgE-dependent_NNP anaphylaxis_NNS in_IN that_DT species_NNS [_NN
        17_CD ]_NN ._. In_IN neither_DT of_IN the_DT models_NNS of_IN "_'' autoimmunity_NN "_'' that_IN we_PRP
        have_VBP studied_VBN (_( i_NNP ._. e_SYM ._. ,_, EAE_NNP ,_, T_NN 1_CD DM_NNP in_IN NOD_NNP mice_NNS )_) was_VBD anaphylaxis_NNS
        associated_VBN with_IN histological_JJ evidence_NN of_IN substantial_JJ mast_NN
        cell_NN degranulation_NN [_NN 14_CD ]_NN (_( data_NNS not_RB shown_VBN )_) ._. Taken_VBN together_RB ,_,
        these_DT findings_NNS suggest_VBP that_IN IgG_NNP 1_CD antibodies_NNS contribute_VBP
        importantly_RB to_TO the_DT development_NN of_IN anaphylaxis_NNS in_IN both_DT of_IN
        these_DT models_NNS ._. On_IN the_DT other_JJ hand_NN ,_, we_PRP can_MD not_RB rule_VB out_RP some_DT
        role_NN for_IN IgE_NNP antibodies_NNS in_IN these_DT reactions_NNS ._.
        Indeed_RB ,_, Liu_NNP 
        et_CC al_NN ._. [_NN 15_CD ]_NN found_VBD that_IN ,_, in_IN NOD_NNP
        mice_NNS that_WDT had_VBD been_VBN immunized_JJ with_IN peptide_NN B_NNP :_: 9_CD -_: 23_CD ,_, treatment_NN
        with_IN both_DT anti_NN FcγRII_NNP /_NN RIII_NNP and_CC anti-_NN IgE_NNP monoclonal_NN
        antibodies_NNS was_VBD required_VBN to_TO prevent_VB anaphylaxis_NNS upon_IN
        challenge_NN with_IN the_DT peptide_NN ._. Interestingly_RB ,_, however_RB ,_, Liu_NNP 
        et_CC al_NN ._. [_NN 15_CD ]_NN did_VBD not_RB detect_VB IgE_NNP
        antibodies_NNS to_TO B_NNP :_: 9_CD -_: 23_CD or_CC B_NNP :_: 13_CD -_: 23_CD in_IN the_DT serum_NN of_IN their_PRP$ NOD_NNP
        mice_NNS ._. By_IN contrast_NN ,_, mice_NNS that_WDT had_VBD been_VBN immunized_JJ with_IN B_NNP :_: 9_CD -_: 23_CD
        peptide_NN at_IN 10_CD or_CC 100_CD μg_NN /_NN dose_NN exhibited_VBN a_DT robust_JJ and_CC
        dose-dependent_JJ IgG_NNP 1_CD antibody_NN response_NN to_TO the_DT peptide_NN [_NN 15_CD ]_NN
        ._. Thus_RB ,_, in_IN both_DT B_NNP :_: 9_CD -_: 23_CD peptide-associated_JJ anaphylaxis_NNS (_( Liu_NNP 
        et_CC al_NN ._. [_NN 15_CD ]_NN )_) and_CC GAD_NNP 65_CD
        peptide-associated_JJ anaphylaxis_NNS (_( our_PRP$ study_NN )_) ,_, anti-peptide_JJ
        IgG_NNP 1_CD antibodies_NNS contribute_VBP to_TO the_DT response_NN ._. However_RB ,_, IgE_NNP
        antibodies_NNS also_RB appear_VBP to_TO contribute_VB to_TO anaphylaxis_NNS to_TO
        B_NNP :_: 9_CD -_: 23_CD peptides_NNS [_NN 15_CD ]_NN ,_, and_CC may_MD also_RB be_VB involved_VBN in_IN our_PRP$
        model_NN ._.
        One_CD point_NN not_RB yet_RB clarified_VBN by_IN the_DT comparison_NN of_IN the_DT
        present_JJ results_NNS ,_, those_DT of_IN Liu_NNP 
        et_CC al_NN ._. [_NN 15_CD ]_NN ,_, and_CC those_DT of_IN Pedotti_NNP
        
        et_CC al_NN ._. [_NN 14_CD ]_NN is_VBZ whether_IN the_DT
        influence_NN of_IN thymic_JJ expression_NN of_IN the_DT self_NN peptide_NN on_IN the_DT
        propensity_NN to_TO develop_VB anaphylactic_JJ reactivity_NN differs_VBZ in_IN
        the_DT EAE_NNP and_CC NOD_NNP T_NN 1_CD DM_NNP models_NNS ._. In_IN the_DT study_NN by_IN Pedotti_NNP et_CC al_NN ._.
        [_NN 14_CD ]_NN ,_, it_PRP was_VBD noted_VBN that_IN the_DT two_CD self_NN peptides_NNS that_WDT
        induced_VBD anaphylactic_JJ reactivity_NN ,_, MOG_NNP 35_CD -_: 55_CD and_CC PLP_NNP 139_CD -_: 151_CD ,_,
        are_VBP not_RB expressed_VBN in_IN the_DT thymus_JJ ,_, whereas_IN the_DT two_CD peptides_NNS
        tested_VBN that_WDT did_VBD not_RB induce_VB anaphylactic_JJ reactivity_NN ,_, PLP_NNP 
        p_NN 178_CD -_: 191_CD and_CC MBPA_NNP 
        C_NNP 1_CD -_: 11_CD ,_, are_VBP expressed_VBN at_IN that_DT site_NN ._.
        However_RB ,_, both_DT GAD_NNP 65_CD and_CC GAD_NNP 67_CD mRNA_NN can_MD be_VB detected_VBN in_IN the_DT
        thymic_JJ medullary_JJ epithelial_NN cells_NNS in_IN mice_NNS [_NN 24_CD ]_NN ._. Thus_RB ,_,
        despite_IN thymic_JJ expression_NN of_IN GAD_NNP 65_CD and_CC GAD_NNP 67_CD at_IN the_DT level_NN
        of_IN mRNA_NN ,_, NOD_NNP mice_NNS spontaneously_RB develop_VBP autoreactivity_NN to_TO
        these_DT islet_NN (_( and_CC brain_NN )_) expressed_VBD proteins_NNS ,_, and_CC
        re-challenge_JJ of_IN mice_NNS that_WDT have_VBP been_VBN immunized_JJ with_IN peptides_NNS
        from_IN GAD_NNP 65_CD results_NNS in_IN severe_JJ anaphylactic_JJ reactions_NNS ._. On_IN the_DT
        other_JJ hand_NN ,_, expression_NN of_IN GAD_NNP 65_CD or_CC GAD_NNP 67_CD protein_NN in_IN the_DT
        thymus_JJ has_VBZ not_RB yet_RB been_VBN reported_VBN ._. Similarly_RB ,_, as_IN reviewed_VBN in_IN
        Liu_NNP 
        et_CC al_NN ._. [_NN 15_CD ]_NN ,_, although_IN several_JJ
        lines_NNS of_IN evidence_NN indicate_VBP that_DT insulin_NN is_VBZ present_JJ in_IN the_DT
        thymus_JJ of_IN mice_NNS and_CC humans_NNS ,_, it_PRP is_VBZ possible_JJ that_IN the_DT specific_JJ
        insulin_NN peptides_NNS that_WDT induced_VBD anaphylaxis_NNS in_IN their_PRP$ study_NN
        are_VBP not_RB ordinarily_RB present_JJ in_IN that_DT site_NN ._. As_IN a_DT result_NN ,_, it_PRP
        has_VBZ not_RB yet_RB been_VBN demonstrated_VBN that_IN anaphylactic_JJ reactions_NNS
        can_MD develop_VB to_TO self_NN peptides_NNS that_WDT are_VBP expressed_VBN in_IN the_DT
        thymus_JJ ._.
        It_PRP should_MD be_VB emphasized_VBN that_IN NOD_NNP mice_NNS have_VBP a_DT partial_JJ
        defect_NN in_IN thymic_JJ negative_JJ selection_NN [_NN 25_CD 26_CD ]_NN ,_, a_DT defect_NN in_IN
        FcγRIIB_NNP (_( that_WDT can_MD negatively_RB regulate_VB anaphylactic_JJ
        reactions_NNS [_NN 27_CD 28_CD ]_NN )_) ,_, and_CC perhaps_RB other_JJ genetic_JJ
        polymorphisms_NNS that_WDT may_MD result_VB in_IN immunological_JJ
        hyperresponsiveness_NNS ._. The_DT same_JJ is_VBZ likely_JJ to_TO be_VB true_JJ in_IN at_IN
        least_JJS some_DT patients_NNS with_IN type_NN 1_CD diabetes_NN ,_, and_CC in_IN patients_NNS
        in_IN the_DT pre-diabetic_JJ phase_NN ._. Therefore_RB ,_, because_IN of_IN the_DT risk_NN
        of_IN induction_NN of_IN anaphylactic_JJ sensitization_NN ,_, extreme_JJ caution_NN
        needs_VBZ to_TO be_VB used_VBN in_IN developing_VBG any_DT type_NN of_IN antigen-specific_JJ
        immunosuppressive_JJ therapy_NN for_IN the_DT prevention_NN or_CC treatment_NN
        of_IN T_NN 1_CD DM_NNP ._. This_DT caution_NN probably_RB should_MD be_VB extended_VBN to_TO all_DT
        attempts_NNS to_TO shift_VB immune_JJ responses_NNS to_TO self_NN or_CC foreign_JJ
        antigens_NNS from_IN a_DT T_NN 
        H_NNP 1_CD to_TO a_DT T_NN 
        H_NNP 2_CD response_NN ._. Indeed_RB ,_, in_IN a_DT recent_JJ phase_NN
        II_NNP clinical_JJ trial_NN ,_, 9_CD %_NN of_IN MS_NNP patients_NNS given_VBN an_DT altered_VBN
        peptide_NN ligand_NN (_( APL_NNP )_) of_IN a_DT myelin_NN basic_JJ protein_NN epitope_NN
        developed_VBD immediate_JJ hypersensitivity_NN reactions_NNS after_IN
        multiple_JJ injections_NNS of_IN the_DT APL_NNP [_NN 29_CD ]_NN ._. Thus_RB ,_, it_PRP would_MD
        appear_VB that_IN great_JJ care_NN must_MD be_VB taken_VBN when_WRB injecting_VBG
        preparations_NNS of_IN putative_JJ "_'' tolerogens_NNS "_'' in_IN attempts_NNS to_TO
        suppress_VB T_NN 
        H_NNP 1_CD -_: mediated_JJ autoimmune_JJ diseases_NNS ._.
      
      
        Methods_NNP
        
          Mice_NNS
          Female_NNP NOD_NNP /_NN LtJ_NNP mice_NNS (_( The_DT Jackson_NNP Laboratory_NNP ,_, Bar_NNP
          Harbor_NNP ,_, ME_NNP )_) ,_, were_VBD maintained_VBN on_IN Lab_NNP Diet_NNP 5_CD K_NNP 52_CD (_( Purina_NNP ,_, St_NNP
          Louis_NNP ,_, MO_NNP )_) ,_, under_IN filter-top_JJ barrier_NN conditions_NNS ._. Mice_NNS
          were_VBD tested_VBN three_CD times_NNS a_DT week_NN for_IN glycosuria_NN using_VBG
          Chemstrip_NNP uGK_NN (_( Roche_NNP Diagnostics_NNPS ,_, Indianapolis_NNP ,_, IN_IN )_) ,_, and_CC
          considered_VBN diabetic_JJ when_WRB tested_VBN positive_JJ (_( glucose_NN levels_NNS
          above_IN 100_CD mg_NN /_NN dL_NN )_) ,_, on_IN three_CD consecutive_JJ occasions_NNS ._.
        
        
          Peptides_NNP
          Three_CD peptide_NN pools_NNS consisted_VBD of_IN :_: G_NNP 7_CD (_( GAD_NNP 206_CD -_: 226_CD ,_, GAD_NNP
          217_CD -_: 236_CD ,_, GAD_NNP 286_CD -_: 300_CD )_) ,_, PD_NNP (_( GAD_NNP K_NNP 458_CD -_: 470_CD R_NN ,_, GAD_NNP 333_CD -_: 345_CD )_) ,_,
          and_CC hen_NN egg_NN lysozyme_NN /_NN ovalbumin_NN (_( HEL_NNP /_NN OVA_NNP ;_: HEL_NNP 81_CD -_: 96_CD ,_, OVA_NNP
          323_CD -_: 339_CD )_) ._. All_DT peptides_NNS were_VBD synthesized_JJ by_IN Research_NNP
          Genetics_NNP (_( Huntsville_NNP ,_, AL_NNP )_) and_CC were_VBD confirmed_VBN >_NN 90_CD %_NN
          pure_JJ by_IN HPLC_NNP and_CC Mass_NNP Spectrometry_NNP analysis_NN ._.
        
        
          Immunizations_NNP
          Mice_NNS (_( 8_CD -_: 9_CD weeks_NNS old_JJ )_) received_VBD three_CD weekly_JJ
          intraperitoneal_NN (_( i_NNP ._. p_NN ._. )_) injections_NNS of_IN 100_CD μl_NN containing_VBG a_DT
          mixture_NN of_IN 200_CD μg_NN each_DT of_IN the_DT G_NNP 7_CD peptides_NNS ,_, the_DT PD_NNP
          peptides_NNS or_CC the_DT HEL_NNP /_NN OVA_NNP peptides_NNS ,_, dissolved_VBN in_IN 50_CD μl_NN of_IN
          sterile_JJ ,_, pyrogen-free_JJ 0_CD ._. 9_CD %_NN NaCl_NNP (_( "_'' saline_NN "_'' )_) and_CC emulsified_JJ
          in_IN an_DT equal_JJ volume_NN of_IN incomplete_JJ Freund_NNP 's_POS adjuvant_NN (_( IFA_NNP )_)
          (_( Difco_NNP Laboratories_NNPS ,_, Detroit_NNP ,_, MI_NNP )_) ._. A_DT peripheral_JJ blood_NN
          sample_NN was_VBD obtained_VBN 2_CD to_TO 3_CD days_NNS before_IN challenge_NN and_CC was_VBD
          analyzed_VBN for_IN antibody_NN response_NN by_IN ELISA_NNP ._. Mice_NNS were_VBD
          challenged_VBN four_CD weeks_NNS after_IN the_DT third_JJ immunization_NN (_( at_IN
          15_CD -_: 16_CD weeks-of-age_JJ )_) by_IN i_NNP ._. p_NN ._. injection_NN of_IN the_DT same_JJ peptide_NN
          pools_NNS (_( 200_CD μg_NN of_IN each_DT peptide_NN )_) dissolved_VBN in_IN saline_NN ._. Mice_NNS
          were_VBD observed_VBN for_IN 30_CD minutes_NNS after_IN challenge_NN for_IN signs_NNS of_IN
          anaphylaxis_NNS ,_, and_CC temperature_NN was_VBD taken_VBN at_IN intervals_NNS of_IN 5_CD
          minutes_NNS ._. As_IN negative_JJ control_NN groups_NNS ,_, mice_NNS were_VBD immunized_JJ
          with_IN an_DT emulsion_NN of_IN IFA_NNP and_CC saline_NN and_CC challenged_VBN with_IN
          saline_NN ,_, and_CC age-gender-matched_JJ non-immunized_JJ mice_NNS were_VBD
          challenged_VBN with_IN the_DT G_NNP 7_CD mixture_NN (_( containing_VBG 200_CD μg_NN of_IN each_DT
          peptide_NN in_IN pool_NN )_) dissolved_VBN in_IN 50_CD μl_NN of_IN saline_NN ._. As_IN an_DT
          additional_JJ control_NN ,_, temperature_NN measurements_NNS were_VBD taken_VBN
          from_IN unmanipulated_JJ (_( non-injected_JJ )_) naïve_NN mice_NNS ._.
        
        
          Passive_NNP systemic_JJ anaphylaxis_NNS
          For_IN passive_JJ systemic_JJ anaphylaxis_NNS ,_, 15_CD -_: week-old_JJ NOD_NNP mice_NNS
          were_VBD injected_VBN i_NNP ._. p_NN ._. with_IN 20_CD μg_NN anti-_NN DNP-IgE_NNP (_( IgE_NNP hybridoma_NN
          =_SYM H_NNP 1_CD DNP-ε-_NNP 26_CD )_) [_NN 16_CD ]_NN dissolved_VBN in_IN 200_CD μl_NN HMEM_NNP
          (_( Gibco-_NNP BRL_NNP ,_, Gaithersburg_NNP ,_, MD_NNP )_) with_IN PIPES_NNP buffer_NN (_( 0_CD ._. 47_CD
          g_SYM /_NN l_NN ,_, Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._. Twenty-four_CD hours_NNS later_RB ,_, mice_NNS
          were_VBD challenged_VBN intravenously_RB (_( i_NNP ._. v_NN ._. )_) with_IN 200_CD μg_NN DNP-HSA_NNP
          (_( Sigma_NNP )_) dissolved_VBN in_IN 200_CD μl_NN saline_NN [_NN 17_CD ]_NN ._.
        
        
          Temperature_NNP measurement_NN
          Rectal_NNP temperatures_NNS were_VBD taken_VBN using_VBG Physitemp_NNP
          (_( Clifton_NNP ,_, NJ_NNP )_) ._. Basal_NNP temperatures_NNS were_VBD recorded_VBN before_IN
          challenge_NN ,_, and_CC temperature_NN readings_NNS were_VBD taken_VBN at_IN 5_CD
          minute_NN intervals_NNS until_IN death_NN from_IN anaphylaxis_NNS or_CC 30_CD
          minutes_NNS post_NN injection_NN ,_, whichever_WDT occurred_VBD first_JJ ._.
          Temperature_NNP measurements_NNS were_VBD performed_VBN in_IN a_DT "_'' blinded_JJ "_''
          fashion_NN ._.
        
        
          IgG_NNP 1_CD and_CC IgG_NNP 2_CD a_DT antibody_NN measurements_NNS
          G_NNP 7_CD ,_, PD_NNP and_CC HEL_NNP /_NN OVA_NNP peptide-specific_JJ IgG_NNP 1_CD and_CC IgG_NNP 2_CD a_DT
          responses_NNS were_VBD measured_VBN in_IN duplicate_VB with_IN mouse_NN sera_NN
          collected_VBD 1_CD to_TO 3_CD days_NNS before_IN challenge_NN ._. EIA_NNP /_NN RIA_NNP 96_CD -_: well_RB
          plates_NNS (_( Corning_NNP Incorporated_NNP ,_, Acton_NNP ,_, MA_NNP )_) were_VBD coated_JJ
          overnight_JJ at_IN 4_CD °_NN C_NNP with_IN a_DT 100_CD μl_NN mixture_NN of_IN each_DT peptide_NN
          preparation_NN in_IN a_DT pool_NN for_IN a_DT total_JJ peptide_NN concentration_NN
          of_IN 30_CD μg_NN /_NN ml_NN diluted_VBN in_IN physiologic_JJ saline_NN ._. After_IN 3_CD washes_NNS
          with_IN phosphate-buffered_JJ saline_NN (_( PBS_NNP )_) and_CC 0_CD ._. 05_CD %_NN Tween_NNP 20_CD
          (_( Sigma_NNP )_) ,_, plates_NNS were_VBD blocked_VBN with_IN PBS_NNP plus_CC 2_CD %_NN BSA_NNP
          (_( Sigma_NNP )_) ,_, and_CC 0_CD ._. 02_CD %_NN sodium_NN azide_NN (_( Sigma_NNP )_) ,_, for_IN 2_CD hours_NNS at_IN
          room_NN temperature_NN (_( RT_NNP )_) ._. Serum_NNP samples_NNS were_VBD diluted_VBN in_IN
          blocking_VBG buffer_NN and_CC incubated_JJ for_IN two_CD hours_NNS at_IN RT_NNP ._. After_IN
          1_CD hr_NN incubation_NN at_IN RT_NNP with_IN 50_CD μl_NN /_NN well_RB of_IN biotinilated_JJ
          secondary_JJ antibodies_NNS ,_, plates_NNS were_VBD developed_VBN with_IN
          Eu-labelled_NNP Streptavidin_NNP (_( PerkinElmer_NNP Life_NNP Sciences_NNPS ,_,
          Boston_NNP ,_, MA_NNP )_) followed_VBN by_IN Enhancement_NNP solution_NN (_( PerkinElmer_NNP
          Life_NNP Sciences_NNPS )_) and_CC read_VB in_IN a_DT 1234_CD Delfia_NNP Fluorometer_NNP
          (_( PerkinElmer_NNP Life_NNP Sciences_NNPS )_) ._. Serum_NNP Ig_NNP values_NNS were_VBD
          interpolated_JJ from_IN standard_JJ curves_NNS obtained_VBN by_IN coating_NN the_DT
          plates_NNS directly_RB with_IN purified_JJ IgG_NNP 1_CD or_CC IgG_NNP 2_CD a_DT (_( PharMingen_NNP )_)
          at_IN a_DT starting_VBG concentration_NN of_IN 500_CD ng_NN /_NN ml_NN ,_, according_VBG to_TO
          the_DT manufacturer_NN 's_POS instructions_NNS ._.
        
        
          Total_NNP IgE_NNP antibody_NN measurement_NN
          Total_NNP IgE_NNP was_VBD measured_VBN in_IN duplicate_VB with_IN mouse_NN serum_NN
          at_IN 1_CD :_: 100_CD dilution_NN by_IN sandwich_NN ELISA_NNP (_( PharMingen_NNP )_)
          according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS [_NN 18_CD ]_NN ._.
        
      
      
        Authors_NNP '_'' Contributions_NNP
        Rosetta_NNP Pedotti_NNP and_CC Maija_NNP Sanna_NNP participated_VBD in_IN the_DT
        design_NN of_IN the_DT experiments_NNS and_CC performed_VBD the_DT peptide_NN
        immunizations_NNS and_CC challenges_NNS in_IN the_DT mice_NNS ,_, measurements_NNS of_IN
        anaphylactic_JJ responses_NNS and_CC ELISA_NNP immunoassays_NNS for_IN
        antibodies_NNS ._. Rosetta_NNP Pedotti_NNP and_CC Maija_NNP Sanna_NNP contributed_VBD
        equally_RB to_TO this_DT study_NN ,_, including_VBG collaborating_VBG in_IN writing_VBG
        the_DT first_JJ draft_NN of_IN the_DT manuscript_NN ._. Mindy_NNP Tsai_NNP participated_VBD
        in_IN the_DT design_NN and_CC execution_NN of_IN the_DT study_NN and_CC the_DT drafting_VBG
        of_IN the_DT manuscript_NN ._. Jason_NNP DeVoss_NNP performed_VBD some_DT of_IN the_DT ELISA_NNP
        immunoassays_NNS for_IN antibodies_NNS ._. Lawrence_NNP Steinman_NNP ,_, Hugh_NNP
        McDevitt_NNP ,_, and_CC Stephen_NNP J_NNP ._. Galli_NNP participated_VBD in_IN experimental_JJ
        design_NN ,_, interpretation_NN of_IN the_DT results_NNS ,_, and_CC revision_NN of_IN the_DT
        manuscript_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ version_NN
        of_IN the_DT manuscript_NN ._.
      
    
  
